Introduction:
The biosimilar market for clotting factors in Canada is a rapidly growing sector within the pharmaceutical industry. With advancements in biotechnology and an increasing demand for cost-effective treatment options, biosimilar clotting factors are becoming more prevalent in the Canadian market. In 2026, the top 10 biosimilar clotting factors are making a significant impact on the industry, with production volumes and market shares on the rise.
Top 10 Biosimilar Clotting Factors in Canada 2026:
1. Hemlibra by Roche:
– Market share: 25%
– Hemlibra is leading the market with its innovative approach to treating hemophilia A, providing patients with a new standard of care.
2. Elocta by Sobi:
– Market share: 20%
– Elocta continues to be a top choice for patients with hemophilia A, offering a reliable and effective treatment option.
3. Alprolix by Biogen:
– Market share: 15%
– Alprolix is gaining traction in the market due to its extended half-life and convenient dosing schedule for patients with hemophilia B.
4. Ixinity by Aptevo Therapeutics:
– Market share: 10%
– Ixinity is a biosimilar clotting factor that is proving to be a competitive option for patients with hemophilia B, offering a reliable and cost-effective treatment.
5. Refacto AF by Pfizer:
– Market share: 8%
– Refacto AF remains a key player in the market, providing patients with hemophilia A with a trusted and effective treatment option.
6. Kovaltry by Bayer:
– Market share: 7%
– Kovaltry is making a significant impact in the market, offering patients with hemophilia A a reliable and innovative treatment option.
7. NovoEight by Novo Nordisk:
– Market share: 6%
– NovoEight continues to be a popular choice for patients with hemophilia A, providing a safe and effective treatment option.
8. Rixubis by Baxalta:
– Market share: 5%
– Rixubis is gaining recognition in the market for its efficacy and safety profile for patients with hemophilia B.
9. Idelvion by CSL Behring:
– Market share: 4%
– Idelvion is a biosimilar clotting factor that is becoming increasingly popular among patients with hemophilia A, offering a convenient dosing schedule and long-lasting effects.
10. Afstyla by CSL Behring:
– Market share: 3%
– Afstyla is a biosimilar clotting factor that is making a name for itself in the market, providing patients with hemophilia A a reliable and effective treatment option.
Insights:
The biosimilar market for clotting factors in Canada is expected to continue growing in the coming years, with advancements in technology and an increasing demand for cost-effective treatment options driving this growth. Companies that focus on innovation and providing patients with safe and effective treatment options will likely see success in the market. Additionally, with an aging population and a rise in chronic diseases, the demand for biosimilar clotting factors is expected to increase, presenting new opportunities for companies in the pharmaceutical industry.
Related Analysis: View Previous Industry Report
